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Summary
 
The pathophysiological relevance of the complement split product C3a as a proinflammatory
mediator is still ill defined. The expression pattern of the human C3a receptor (C3aR) can pro-
vide important clues for the role of this anaphylatoxin in inflammation. There is strong evi-
dence for C3aR expression on basophils, and eosinophils, but additionally, only on tumor cell
lines of leukemic or hepatic origin. It is unclear whether neutrophils also express the C3aR,
but need a costimulus provided by eosinophils for certain biological responses, or whether neu-
trophils lack the C3aR and respond to C3a via a secondary stimulus generated by eosinophils,
i.e., by an indirect mode. In the present study, polyclonal antiserum raised against the second
extracellular loop of the C3aR was used to characterize C3aR expression on peripheral blood
leukocytes. For high degree purification of neutrophils, a negative selection method was estab-
lished that decreased the contamination with CD9
 
bright
 
1
 
 eosinophils down to 
 
,
 
0.2%. Flow
cytometric analyses, functional assays, and binding assays on highly purified neutrophils con-
firmed C3aR expression and coupling. Monocytes were identified as an additional C3aR-pos-
itive cell population of the peripheral blood. The expression of the C3aR on eosinophils could
be confirmed. In contrast, the receptor could not be detected on unchallenged B or T lympho-
cytes (or lymphocyte-derived Raji cells).
 
T
 
he anaphylatoxic peptides C3a, C4a, C5a, and C5a–
desArg are generated during complement activation.
They are considered proinflammatory mediators with some
immunomodulatory properties (1–3). There is detailed know-
ledge about C5a and its specific receptor, including bacte-
rial infection models in C5a receptor knockout mice (4–6).
In contrast, studies on C3a and its receptor (C3aR)
 
1
 
 have
been almost neglected in the human system for a long time.
Only recently has attention been focused on this anaphyla-
toxin, culminating in the recent cloning of the C3aR by us
and others (7–9). There is an ongoing discussion about the
expression pattern of the human C3aR, in particular on
blood cells, and the thereby implied physiological impor-
tance of C3a. It is now broadly accepted that the human
C3aR is expressed on basophils (10, 11), and mast cells
(12), and there are functional data strongly implying its ex-
pression on eosinophils (13, 14). Until now, there was no
direct proof for C3aR expression on human monocytes.
However, there is some evidence. The expression of the
C3aR can be induced on U937 cells by dibutyryl cAMP or
IFN-
 
g
 
 (15, 16), a treatment that drives these monomyelo-
blastic cells closer to the mature monocyte–macrophage
phenotype. Additionally, C3a modulates lipopolysaccharide-
induced gene expression and protein synthesis on PBMCs
(17). The publications on neutrophils are contradictionary.
It is unclear whether neutrophils actually express the C3aR
(15, 18–20), but need a costimulus provided by eosinophils
for certain biological responses, or whether neutrophils lack
this receptor (21) and respond to C3a by an indirect mode,
via a secondary stimulus generated by eosinophils (13).
Similarly, the presence in standard density gradient PMN
preparations (e.g., Polymorphprep
 
Ô
 
) of up to 4% of eosin-
ophils could account for the specific binding of [
 
125
 
I]–C3a
to PMNs (15), and the cloning of the C3aR from cDNA
of lipopolysaccharide-activated neutrophils (7). In parallel,
the C3aR has been cloned from cDNA of induced U937
cells (8), and had also been published as an orphan receptor
from a differentiated HL-60 cell cDNA library (9). Flow
cytometric analysis suggested C3aR expression on human
Burkitt lymphoma–derived Raji cells, on neutrophils, and
on monocytes (9). The goal of the present study was to
 
1
 
Abbreviations used in this paper:
 
 C3a, an anaphylatoxic peptide generated
from the complement component C3; C3aR, C3a receptor; [Ca
 
2
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]
 
i
 
, con-
centration of free cytosolic Ca
 
2
 
1
 
, GAPDH, rat glyceraldehyde-3-phos-
phate dehydrogenase used as housekeeping gene.
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clarify the expression pattern of the human C3aR on sub-
populations of peripheral blood leukocytes. To this aim,
flow cytometry using a polyclonal Ab specific for the C3aR
was combined with functional assays, binding studies, and
Northern blots on highly purified neutrophils and on mono-
cytes with a minimized contamination with C3aR-bearing
granulocytes. Our results indicate that the C3aR is ex-
pressed on neutrophils, monocytes, and eosinophils. In con-
trast, the C3aR neither seems to be expressed on B or T
lymphocytes, nor on Raji cells.
 
Materials and Methods
 
Reagents.
 
Human C3a was purchased from Advanced Re-
search Technologies (San Diego, CA). The C3a analogue syn-
thetic peptide P117 (LRRQAWRASALGLAR) (8) (amino acids
63–77 of hC3a), and the control peptide P252 (YTTDDYG-
HYDD) were prepared by solid-phase synthesis. Anti-CD16–PE
(clone 3G8) and FITC-labeled goat anti–rabbit IgG1 were ob-
tained from Dianova (Hamburg, Germany). Anti-CD14–PE, PE-
and FITC-coupled mouse control IgG1, anti-CD9 (clone ALB6),
and Optilyse B
 
Ô
 
 were supplied by Immunotech (Hamburg,
Germany). Anti-CD3–Cychrome
 
Ô
 
 was purchased from Phar-
Mingen (Hamburg, Germany), whereas anti-CD19–PE was from
Biozol (Eching, Germany). All marker mAbs were mouse IgG1.
All other chemicals were purchased from Sigma Chemicals (De-
isenhofen, Germany).
 
Cell Lines, Cell Culture Conditions.
 
The rat basophilic leuke-
mia cell line RBL-2H3 (American Type Culture Collection
[ATCC], Rockville, MD) stably transfected with C3aR cDNA
was grown as described elsewhere (7). The cell culture conditions
of U937 cells (ATCC) and the C3aR induction by dibutyrylic
cAMP have been earlier described (15). For the culture of Raji
cells (ATCC) RPMI-1640 (LIFE Technologies, Eggenstein, Ger-
many) supplemented with 10% heat-inactivated FCS was used.
 
The Preparation of Polyclonal Rabbit Serum Directed Against the
Human C3aR.
 
The cDNA of the second extracellular loop of
the C3aR (amino acids 170–315) was amplified by PCR and sub-
cloned into the pGEX5X-1 expression plasmid (Pharmacia Bio-
tech, Inc., Piscataway, NJ). Expression and purification of the re-
sulting glutathione–S transferase fusion protein were performed
according to the instructions of the manufacturer. To raise poly-
clonal Abs against the human C3aR, rabbits were immunized
twice with 250 
 
m
 
g of the fusion protein, followed by four inocu-
lations of 125 
 
m
 
g each (HRP, Inc., Denver, CO).
 
Flow Cytometric Analyses of PBLs and Raji Cells with Polyclonal
Rabbit Anti-C3aR Serum.
 
PBLs were prepared from EDTA
blood of healthy donors. Erythrocytes were lysed by NH
 
4
 
Cl. The
remaining PBLs were washed twice (PBS at 4
 
8
 
C) and resus-
pended at a density of 1 
 
3
 
 10
 
7
 
 cells/ml. Raji cells grow in sus-
pension and tend to clump. Therefore, after harvesting and two
washes in ice-cold PBS, these cells were filtered through a 30-
 
m
 
m
nylon mesh. 5 
 
3
 
 10
 
5
 
 cells in a total volume of 100 
 
m
 
l were incu-
bated for 30 min with the polyclonal rabbit serum (1:4,000) raised
against the C3aR. In parallel, the cells were always incubated
with 1:4,000 diluted rabbit preimmune serum (of the same ani-
mal) as a negative control for C3aR-independent binding of rab-
bit IgG, and PBS providing the negative control for nonspecific
binding of the secondary antibody. After two washes, the cell pel-
let was resuspended and incubated for 30 min in PBS containing
FITC-labeled goat anti–rabbit IgG (1:200) and PE- or Cy-
chrome
 
Ô
 
-labeled pretitrated anti-CD mAb’s. Gating for the dif-
ferent leukocyte subpopulations was based on a combination of
forward scatter, side scatter, and these CD markers. Anti-CD16
was used for the subsequent differentiation between neutrophils
(CD16
 
bright
 
1
 
) and eosinophils (CD16
 
dim
 
1
 
) (22). Anti-CD14 was
used for the identification of monocytes, anti-CD3 for T lym-
phocytes, and anti-CD19 for B lymphocytes (23). After two addi-
tional washes, the PBLs were resuspended in 100 
 
m
 
l of ice-cold
buffer. Finally, the cells were assessed in the flow cytometer FAC-
Scan
 
Ò
 
 and analyzed by CELLQuest
 
Ô
 
 Software (Becton Dickinson,
Heidelberg, Germany).
 
Isolation of Human PMNs.
 
Highly purified neutrophils were
prepared from citrate-anticoagulated blood of healthy human do-
nors. PMNs were prepared by density centrifugation using Poly-
morphprep
 
Ô
 
 (Nycomed, Oslo, Norway), according to the in-
structions of the manufacturer. For the preparation of highly
purified neutrophils that are only minimally contaminated with
eosinophils, it was important to collect only the clearly defined
upper granulocyte layer. The harvested PMNs were washed twice
with PBS. The cells were counted and resuspended in PBS to 1 
 
3
 
10
 
7
 
 cells/ml. The cells were either immediately further purified
(see CD9 depletion of eosinophils), or kept on ice until func-
tional analyses.
 
Purification of Neutrophils by Depletion of CD9
 
bright
 
1
 
 Eosinophils.
 
For anti-CD9 depletion of eosinophils, the granulocytes obtained
by Polymorphprep
 
Ô
 
 were incubated for 30 min in a solution
of an anti-CD9 mAb (10 
 
m
 
g/ml) in PBS at 4
 
8
 
C. The cells were
washed twice, and incubated for 20 min in a solution of goat
anti–mouse IgG coupled to microsphere magnetic beads at a con-
centration of 312.5 
 
m
 
g/ml (Dianova). The CD9
 
bright
 
1
 
 cells were
selected from the CD9
 
dim
 
1
 
 neutrophils by the use of a magnetic
separator (Dynal, Hamburg, Germany) (three times). The result-
ing highly purified neutrophils were resuspended at a density of 1 
 
3
 
10
 
7
 
 cells/ml. The purity of the neutrophil preparation was always
checked by microscopic examination with Kimura staining (24)
and Diff-Quick
 
Ô
 
 staining (Baxter Dade, Düdingen, Switzer-
land), as well as by flow cytometric analysis using anti-CD16–PE.
 
Preparation of Monocytes for Northern Blot Analyses.
 
First, PBMCs
were isolated from blood of healthy human donors through centrifu-
gation on a standard Ficoll gradient (Ficoll-Paque
 
Ô
 
; Pharmacia
Biotech, Inc., Uppsala, Sweden). Then, the monocytes were en-
riched within the fraction of mononuclear cells using their adher-
ence to cell culture dishes (25) (incubation for 2 h at 37
 
8
 
C in
RPMI 1640 medium, supplemented with 10% heat-inactivated
FCS). After washing off the nonadherent cells, the monocyte-
enriched PBMCs were detached from the plastic surface with cell
dissociation solution (Sigma). 1,000 stained cells (Diff-Quick
 
Ô
 
)
were counted. This procedure yielded monocytes of 
 
>
 
85% pu-
rity as additionally confirmed by flow cytometry (anti-CD14). All
contaminating cells were lymphocytes, whereas no granulocytes
were found.
 
Fura-2 Assay of Neutrophils (in Suspension).
 
The measurement
of free cytosolic Ca
 
2
 
1
 
 ([Ca
 
2
 
1
 
]
 
i
 
) on neutrophils in suspension was
performed using Fura-2/AM and the Luminescence Spectro-
meter LS 50B (Perkin Elmer, Beaconsfield, UK). The Fura-2/
AM–loading (Calbiochem, Bad Soden/Taunus, Germany) and
measurement (final concentration: 2 
 
3
 
 10
 
5
 
 cells/ml) were per-
formed exactly as described earlier (15).
 
Flow Cytometric [Ca
 
2
 
1
 
]
 
i
 
 Measurements of Monocytes.
 
The PBMCs
from a standard Ficoll gradient (see above) were washed in PBS.
Then, the cells, at a density of 1 
 
3
 
 10
 
7
 
/ml, were loaded in a
polypropylene tube with 5 
 
m
 
M Fluo3-AM (ICN Biomedicals
GmbH, Eschwege, Germany). The fluorescence indicator was 
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applied in RPMI-1640 medium, containing 10% FCS, and 0.2%
Pluronic
 
Ò
 
 F-127 (Sigma). After 25 min in a standard CO
 
2
 
 cell in-
cubator at 37
 
8
 
C the PBMCs were washed twice. Finally, the
Fluo3-loaded cells were resuspended in RPMI 1640 medium
supplemented with 10% FCS, to a density of 1 
 
3
 
 10
 
7
 
 cells/ml.
To a 50-
 
m
 
l aliquot of this cell suspension 150 
 
m
 
l of RPMI me-
dium with or without stimulus was added. Exactly 10 s after the ad-
dition of the stimulus, the flow cytometric determination of 10,000
cells, lasting 
 
z
 
5 s, was started.
 
Preparation of Monocytes for Competitive Binding Studies.
 
PBMCs
were prepared on a Ficoll gradient as described above. The
mononuclear cells were further purified through positive selec-
tion with CD14-coupled MACS
 
Ô
 
 (Miltenyi Biotec, Bergisch-
Gladbach, Germany) (26) exactly following the manufacturer’s
protocols. The purity was checked by flow cytometric analyses
(CD14 staining), and microscopic control of Diff-Quick
 
Ô
 
stained cells. Monocytes accounted for more than 90% of the re-
sulting cell preparation. The remaining 10% were predominantly
lymphocytes. No granulocytes were found within 1,000 stained
cells.
 
Northern Blot Analyses of Human Monocytes, Raji, and U937
Cells.
 
Preparation of mRNA, Northern blotting, preparation of
riboprobes, hybridization, and chemoluminescence detection of
C3aR mRNA and mRNA of the rat glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (27) were performed as described pre-
viously (8, 16). All samples, which are shown in the Northern
blot, were processed simultaneously.
 
Competitive [
 
125
 
I]–hC3a Binding Studies
 
Radiolabeling of C3a
was performed with Iodogen as described for C5a and C3a (16).
The purified neutrophils or monocytes were washed twice and
resuspended in PBS. In the case of monocytes, 0.1% of sodium
azide was added. The cells were stored on ice before use. For
competitive [
 
125
 
I]–C3a binding assays different concentrations of
unlabeled C3a in PBS as indicated were mixed in quadruplicates
with a constant concentration of a [
 
125
 
I]–C3a solution (about
40,000 cpm for neutrophils and 50,000 cpm for monocytes per well)
in a microtiter plate (Greiner, Frickenhausen, Germany). The bind-
ing reaction was started by addition of 25 
 
m
 
l prewarmed (see be-
low) cell suspension of 2 
 
3
 
 10
 
7
 
 cells/ml (total reaction volume,
60 
 
m
 
l). After 30 min of incubation at 37
 
8
 
C for neutrophils, or at
room temperature for monocytes, cell-bound and free [
 
125
 
-I]–
rhC3a were separated by filtration of 55 
 
m
 
l through a premoist-
ened (PBS) microtiter membrane plate (Multiscreen
 
Ô
 
 HV, 0.45
 
m
 
m, MAHV N45; Millipore, Molsheim, France) using a vacuum
manifold (Millipore). The wells were washed twice, dried by a
heat lamp, and punched out with a multiple punch assembly (Milli-
pore). Punched-out membranes were counted on a 
 
g
 
-counter
(Canberra Packard, Dreieich, Germany). The data were used to
calculate dissociation constant (
 
K
 
d
 
) and number of receptors per
cell via iterative curve fitting using a commercial software
(Ligand, Biosoft, Cambridge, UK).
 
Results and Discussion
 
Polyclonal Anti-C3aR Serum at a Dilution of 1:4,000 Com-
bined with a C3aR Northern Blot Can Be Used to Demonstrate
the Absence of this Receptor on Raji Cells.
 
For flow cytometric
analysis, a rabbit antiserum was raised against the second
extracellular loop of the C3aR. Its optimal dilution of 1:4,000
was determined on a rat basophilic leukemia cell line
(RBL-2H3 cells) stably expressing the human C3aR (7)
and on nontransfected RBL cells (data not shown). Using
these conditions, no difference between the fluorescence
caused by immune, or preimmune sera, or the buffer con-
trol could be detected on Raji cells (data not shown). To
confirm the thereby suggested absence of the C3aR on the
cell surface of these cells, C3aR Northern blots with
poly(A
 
1
 
) RNA from Raji cells were performed (Fig. 1).
RNA from dibutyryl cAMP-induced (Boehringer, Mann-
heim, Germany) (U
 
i
 
) and native U937 cells (U
 
f
 
) was ap-
plied as control. As described before (8), a prominent hy-
bridization band at 
 
z
 
2.4 kb, and a weak band at about 4 kb
(16) could be detected. In contrast, even with 1 
 
mg of
poly(A1) RNA from Raji cells no C3aR transcript could
be detected. The integrity of the Raji cell mRNA was af-
firmed by rehybridization with a probe for the housekeep-
ing gene GAPDH (27), and the sharp rRNA bands in the
corresponding gel. Consistent with these results, we could
not detect any specific [125I]–hC3a binding on Raji cells
(data not shown). The discrepancy to the results of Rogli
et al. (9) who described C3aR expression on Raji cells an-
tigenetically could be due to clonal differences of the ana-
lyzed cells, or the low serum dilution (1:200) used in their
study. In our animals, such high concentrations result in
high nonspecific binding of the preimmune serum on cer-
tain cell types.
´ c
Figure 1. C3aR mRNA is found in human monocytes but not in Raji
cells. Northern blot (a) and corresponding denaturing ethidium bromide–
stained agarose gel (b) of poly(A1) RNA from nondifferentiated U937 cells
(Uf) (z6,500 C3aR per cell; reference 16), U937 cells with induction of
their C3aR expression by dibutyrylic cAMP (Ui) (z30,000 per cell; ref-
erences 15, 16), Raji cells (Ra), and monocytes (Mo), enriched from
PMNCs by adherence. The intensity of the ribosomal bands indicated
that similar concentrations of RNA were loaded in each lane. Addition-
ally, the blot was rehybridized with a GAPDH probe as internal standard.202 C3a Receptor on Human Neutrophils and Monocytes
Flow Cytometric Analyses with Polyclonal Rabbit Anti-C3aR
Serum Indicate C3aR Expression on Human Neutrophils, Eosin-
ophils and Monocytes, but Not on T or B Lymphocytes. Periph-
eral blood leukocytes were examined flow cytometrically
for C3aR expression. The histograms for the different cell
types (Fig. 2) indicate that the highest degree of C3aR ex-
pression can be found on neutrophils, whereas eosinophils
showed weaker staining. The histogram of monocytes is
remarkably widespread, suggesting a high diversity in the
degree of C3aR expression. Possibly, monocyte subpopu-
lations (or monocytes in different states of activation) exist
that vary in their extent of C3aR expression. B and T lym-
phocytes did not show any C3aR-specific fluorescence as
compared with the preimmune serum. The mean values of
the fluorescence (FL-1) from cells obtained from five dif-
ferent donors confirmed for neutrophils, eosinophils, and
Figure 2. Flow cytometric analyses using polyclonal rabbit anti-C3aR serum suggests C3aR expression on human neutrophils, eosinophils, and mono-
cytes, but not on T or B lymphocytes. The fluorescence values (FL-1) of different subpopulations of peripheral blood of one healthy human individual
are depicted as histograms using anti-C3aR immune serum, preimmune serum (both sera diluted 1:4,000), and PBS. These histograms were based on
the corresponding gating of neutrophils, eosinophils, monocytes, T and B lymphocytes according to their specific pattern in forward and side scatter, and
cell population–specific CD markers For each cell type, one typical experiment of a total of five is depicted.
Table 1. Statistical Evaluation of Flow Cytometric Analyses Using Polyclonal Rabbit Anti-C3aR Serum Suggests C3aR Expression on 
Human Neutrophils, Eosinophils, and Monocytes, but not on T or B Lymphocytes
Neutrophils Eosinophils Monocytes T lymphocytes B lymphocytes
Anti-C3aR serum 45.5 6 3.6* 23.0 6 3.9* 24.4 6 5.7* 3.2 6 1.2 10.5 6 0.6
Negative serum 11.3 6 2.7 9.5 6 2.1 10.4 6 2.9 3.3 6 1.2 11.1 6 0.8
PBS 3.3 6 0.6 6.6 6 1.2 4.9 6 1.9 2.6 6 1.0 2.8 6 0.2
The mean fluorescence values corresponding to FL-1 in Fig. 2 using anti-C3aR immune serum, preimmune serum (serum dilutions of 1:4,000), and
PBS were determined. Blood of (n 5 5) different healthy donors was analyzed in independent experiments. Mean 6 SD of the mean fluorescence
values of neutrophils, eosinophils, monocytes, T lymphocytes, and B lymphocytes are depicted. The significance of the difference between the fluo-
rescence obtained with the anti-C3aR serum and the control serum (P .0.999 in the Student’s t test) is indicated by asterisks.203 Martin et al.
monocytes significant differences between the fluorescence
obtained by preimmune and C3aR immune serum (Table 1).
The gap between the mean fluorescence obtained with the
two sera on neutrophils was similar to that on RBL cells,
expressing z32,000 C3aR per cell (data not shown).
CD9 Antigen Is Highly Expressed on Human Eosinophils: It
Can Be Used for High Degree Purification of Neutrophils from
PMN Preparations by Negative Selection. To show that C3a-
mediated functional responses of neutrophils (including
specific [125I]–C3a binding) are independent of the pres-
ence of other cells like eosinophils, a negative selection
method for the purification of highly enriched neutrophils
was developed. It was based on the depletion of the con-
taminating eosinophils from PMN preparations to mini-
mize preactivation of the purified neutrophils, which could
otherwise interfere in functional assays. A mouse anti-CD9
mAb bound to eosinophils and only a subpopulation (de-
pending on the donor: 5–25%) of neutrophils (CD16bright1)
(data not shown) confirming earlier reports (28–30). Based
on this mAb, and anti-mouse IgG bound to magnetic beads,
CD9dim1 neutrophils could be highly enriched by magnetic
sorting. The purity of each neutrophil preparation was con-
trolled by three independent methods: Staining by Diff-
QuickÔ and Kimura (counting 2,000 cells), and flow cy-
tometry using an anti-CD16 mAb. By preselecting normal
donors with a maximum of 2% of eosinophils, the corre-
sponding highly purified neutrophil preparations were con-
taminated with less than 0.2% of eosinophilic granulocytes,
and less than 0.2% of mononuclear cells, almost exclusively
lymphocytes.
C3a and a C3a Analogue Synthetic Peptide Induce a Dose-
dependent Increase of [Ca21]i in Highly Purified Human Neutro-
phils. Highly purified neutrophils isolated from three
healthy donors were analyzed in the Fura-2/AM assay for
their functional response to C3a, and the C3a analogue
synthetic peptide P117 (Fig. 3). Highly purified neutrophils
responded to C3a and P117 in a dose-dependent manner
with an ED50 of 2.5 6 1.0 nM, and 62.3 6 2.5 nM (n 5
3), respectively. Up to 10 mM of the irrelevant peptide
P252 did not cause any elevation of the baseline in neutro-
phils (35 6 10 nM of [Ca21]i). Similar results (concerning
ED50 and peak height) were obtained in parallel experi-
ments using less purified granulocytes obtained from the
same donors, which contained up to 5% eosinophils (data
not shown). One can draw the following conclusions: (a)
Being present in such a low percentage, the contaminating
cells can not account for the Ca21 signal determined in the
highly purified neutrophil suspension. (b) The peak Ca21
level of highly purified neutrophils was already reached
z5–10 s after the addition of C3a. The short interval be-
tween C3a addition and the response of neutrophils argues
additionally against an indirect C3a effect. The response of
neutrophils would have to be mediated by the fast synthesis
of a neutrophil-activating factor or its fast release from eosin-
ophils. (c) This factor would then have to be already in
abundance when only ,0.2% of eosinophils are present. (d)
Nevertheless, other C3a-dependent functional responses of
neutrophils might be influenced by eosinophils, as described
for neutrophil polarization (13). In contrast with the fast
Ca21 response, neutrophil polarization only slowly increases
within 10–40 min after C3a addition. A minimum of z3%
of eosinophils is needed for polarization.
Taken together, the fast C3a-triggered increase in cyto-
solic Ca21 of neutrophils seems to be independent of eosin-
ophils. These data strongly suggest the expression of the C3aR
on neutrophils and confirm the data obtained by FACSÒ
demonstrating C3aR expression on these cells.
Highly Purified Neutrophils Show Essentially the Same
[125I]–hC3a Binding as Less Purified Neutrophils in the Presence
of Eosinophils. As further evidence for the expression of
the C3aR on neutrophils, competitive [125I]–hC3a binding
studies were performed on highly purified neutrophils
(Fig. 4, closed circles). By iterative curve fitting a Kd of 4.5 6
3.4 nM and a number of 23,700 6 14,800 C3aR per cell
were calculated (n 5 3 experiments). These data again
strongly indicate that the C3aR is indeed present on neu-
trophils. If only the small percentage of eosinophils (,0.2%)
accounted for the observed specific C3a binding, the few
eosinophils would have to express an unlikely, extremely
high number of C3aR per cell (.10,000,000). Addition-
ally, if this was the case, the specific [125I]–hC3a binding
should then depend on the percentage of C3aR-bearing
contaminating eosinophils. However, we observed an es-
sentially unchanged binding behavior on less purified neu-
trophils from the same donor (Fig. 4, open circles).
Additional Assays to Confirm C3aR Expression on Mono-
cytes. Flow cytometry using 1:4,000 diluted polyclonal
anti-C3aR serum had strongly suggested C3aR expression
Figure 3. Highly purified human neutrophils (,0.2% of eosinophils)
still respond to C3a and a C3a-analogous synthetic peptide (P117) with an
increase in cytosolic Ca21. The response was determined in a Fura-2/AM
assay in suspension. The irrelevant peptide P252 served as negative con-
trol. Depicted are mean 6 SD (n 5 3) of one typical experiment out of
three.204 C3a Receptor on Human Neutrophils and Monocytes
on human monocytes (see Fig. 2) Again, we wanted to
confirm these data by independent methods: C3aR North-
ern blot, C3a-dependent [Ca21]i response, and competitive
[125I]–hC3a binding studies.
A High Steady-state Level of C3aR mRNA Is Detectable in
Monocytes. Poly(A1) RNA was prepared from monocytes
for C3aR Northern blots. For this assay, monocytes (CD141)
had been enriched (.85%) from the fraction of mononu-
clear cells (Ficoll) by their adherence to cell culture dishes.
As judged by microscopy of the stained cells, and con-
firmed by flow cytometry (data not shown), lymphocytic
cells accounted for the residual ,15%, whereas granulocytes
were completely eliminated by this procedure (,0.1%).
This contamination was considered to be tolerable, because
on B or T lymphocytes no C3aR-specific fluorescence had
been detected before with the polyclonal anti-C3aR serum
(see Fig. 2). 200 ng of monocyte poly(A1) RNA was hy-
bridized with a C3aR riboprobe in the same Northern blot
as described above for mRNA of U937 and Raji cells (see
Fig. 1). Strong and typical hybridization signals for C3aR
mRNA could be detected for monocytes. According to the
weak hybridization band obtained with the GAPDH probe,
an unexpected high steady-state level of C3aR mRNA
seems to be present in monocytes.
Unfortunately, poly(A1) RNA from highly purified neu-
trophils could only be prepared in a semidegraded manner,
not suitable for Northern blots.
Human Monocytes Respond to C3a, or the C3a Analogue
Synthetic Peptide P117, with an Increase in [Ca21]i. The C3a-
dependent Ca21 increase in monocytes was determined
flow cytometrically starting 10 s after application of the
ligand, and compared with the response of monocytes to
C5a. Diff-QuickÔ staining revealed that no granulocytes
were present within 1,000 cells of the PMNC preparation,
and that all contaminating cells (z80%) were of lympho-
cytic origin. For this functional assay, monocytes were
gated within the PBMCs according to forward scatter and
side scatter (Fig. 5, top). Flow cytometric analyses of an ali-
quot of this PMNCs preparation using CD14 (LPS recep-
tor) as marker for monocytes confirmed that the selected
gating was appropriate for monocytes (data not shown).
The monocytes responded with an increase in Fluo3-deter-
mined fluorescence to a C3a stimulus, as compared with
the buffer control (Fig. 5, bottom). As judged by the mean
fluorescence values, the maximal C3a response of mono-
cytes is reached at concentrations of C3a near 5–10 nM, simi-
lar to neutrophils (data not shown). Intriguingly, the
monocytes did not respond homogeneously to C3a. With in-
creasing C3a concentrations progressively more cells switched
from a fluorescence value corresponding to the buffer con-
trol to a distinctly higher fluorescence state. However, even
at maximal C3a concentrations a portion of the gated cell
population did not show any increase in Ca21. The same
effect was observed after stimulation with the C3a analogue
peptide P117. P252 served again as negative control (data
not shown). In kinetic studies with increased incubation
times after C3a application of up to 1 min (equivalent to
the approximate duration of the response), a similar pro-
portion of monocytes seemed to be non-C3a responsive
(data not shown). In contrast, almost all gated cells re-
sponded homogeneously after stimulation using a maximal
concentration of recombinant C5a (20 nM). These data
would most likely suggest that there is a subpopulation of
monocytes lacking the ability to react to C3a. These might
correspond to the heterogeneous distribution of the C3aR
as determined with the polyclonal anti-C3aR serum (see
Fig. 2). If this is the case, it remains to be investigated whether
the inhomogeneity actually reflects different subsets within
monocytes or monocytes at different states of preactivation
caused by the cell preparation. Similarly, functional subpop-
ulations within neutrophils have been described for the IL-8
receptor (31). B or T lymphocytes did not react to C3a in
this assay (data not shown). There is no evidence for C3aR
expression on lymphocytes. Keeping in mind that no
C3aR could be detected antigenetically, and that the re-
sponse reaches its maximum already 10–15 s after stimulus
application, it is very unlikely that lymphocytes stimulated
by C3a would influence the Ca21 response of monocytes.
Specific C3a Binding in the Nanomolar Range Can Be Detected
in Purified Monocytes. For competitive [125I]–hC3a binding
studies monocytes were enriched from PBMCs through
positive selection with CD14-coupled MACSÔ, resulting
in a purity of z90–98%, as described earlier (26). All con-
taminating cells were lymphocytic cells. One representative
binding study with increasing concentrations of nonlabeled
Figure 4. C3aR demonstrated on highly purified human neutrophils
(,0.2% of eosinophils) in competitive [125I]–hC3a binding studies. A
constant concentration of [125I]–hC3a (z40,000 cpm) was displaced by
increasing concentrations of nonlabeled C3a as well as the C3a analog
peptide P117, and the irrelevant peptide P252. Neutrophils from the
same individual, undergoing only a mock treatment instead of an anti-
CD9 depletion, were analyzed in parallel. Mean 6 SD (n 5 4) of one
typical experiment out of three are given. (The difference in the percent-
age of eosinophils due to anti-CD9 depletion was factor 3–5 in these ex-
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C3a on these highly purified monocytes is depicted (Fig.
6). These data clearly show specific C3a binding on human
monocytes, as confirmed by the binding of the control
peptides. The half-maximal competitive effect on mono-
cytes of (n 5 3) different donors was reached at concentra-
tions of C3a (10–100 nM) ten times higher than on neu-
trophils (see also Fig. 4), suggesting differences in the C3aR
affinity (n 5 3 experiments; Kd, 48.2 6 23 nM; 52,500 6
14,000 C3aR per monocyte). One possible explanation for
this difference would be the coupling of the receptor to
different G proteins in the two different cell types; it is
known that G protein coupling influences the receptor af-
finity (32) as recently demonstrated for the high affinity
binding sites of the C5a receptor (33). Theoretically, one
Figure 5. Human monocytes respond inhomogeneously to C3a.
PBMCs (no granulocytes within 1,000 stained cells) were loaded with
Fluo3-AM as fluorescence indicator of free cytosolic Ca21. Monocytes
were gated as indicated in the upper panels. The histograms of the fluo-
rescence intensity (FL-1) resulting z10 s after stimulation with buffer or
20 nM of C5a, and increasing concentrations of C3a, respectively, are de-
picted. The response of monocytes to the C3a analogue peptide P117 was
similar (data not shown).
Figure 6. C3aR demonstrated on highly purified human monocytes in
competitive [125I]–hC3a binding studies. Monocytes were highly purified
by anti-CD14 MACSÔ (in this particular experiment, z96%, 4% lym-
phatic cells, ,0.2% granulocytes). A constant concentration of [125I]–hC3a
(z50,000 cpm) was displaced by increasing concentrations of nonlabeled
C3a as well as the C3a analog peptide P117, and the irrelevant peptide
P252. Mean 6 SD (n 5 4) of one typical experiment out of three are
given.
could also speculate that different subtypes of the C3aR
might exist on monocytes and neutrophils. However, pres-
ently there is no other evidence for that. This phenomenon
has to be clarified in future studies.
In all experiments reported in these studies the method
of purification of neutrophils or monocytes was selected
and optimized in order to support the main aim of this pa-
per, the determination of cellular subsets expressing the
C3aR. One might expect a modulation of C3aR expression
depending on the state of (pre-)activation of monocytes and
neutrophils. Therefore, we are reluctant to judge quantita-
tively and to compare the data for one cell type obtained in
different assays. It will be interesting to see in future studies,
e.g., whether the adherence of monocytes or the binding
of the anti-LPS antibody (CD14) in vitro or the migration
of monocytes into inflamed tissue in vivo influences C3aR
expression and/or the C3a responsiveness of this cell type.
Taken together, we have shown in the present study an-
tigenetically, functionally, and by ligand binding the ex-
pression of the C3aR on human neutrophils and mono-
cytes. For monocytes, we could provide further evidence
by C3aR mRNA Northern blots. Additionally, the bind-
ing of the anti-C3aR serum on human eosinophils con-
firmed C3aR expression on this cell type. The C3aR can
also be found on human basophils (10, 11), and mast cell
lines (12). The emerging broad expression pattern of the
C3aR on all peripheral blood cells of myeloid origin sug-
gests an until now underestimated physiological and patho-
physiological role of C3a in man.206 C3a Receptor on Human Neutrophils and Monocytes
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